US Stock MarketDetailed Quotes

RGNX Regenxbio

Watchlist
  • 5.740
  • -0.270-4.49%
Trading Mar 11 11:26 ET
284.39MMarket Cap-1.15P/E (TTM)

About Regenxbio Company

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Company Profile

SymbolRGNX
Company NameRegenxbio
Listing DateSep 17, 2015
Issue Price22.00
Founded2008
CEOMr. Curran Simpson
MarketNASDAQ
Employees344
Fiscal Year Ends12-31
Address9804 Medical Center Drive
CityRockville
ProvinceMaryland
CountryUnited States of America
Zip Code20850
Phone1-240-552-8181
Websitehttp://www.regenxbio.com

Company Executives

  • Name
  • Position
  • Salary
  • Curran Simpson
  • Director, President and Chief Executive Officer
  • 2.95M
  • Patrick J. Christmas
  • Executive Vice President and Chief Legal Officer
  • --
  • Dr. Olivier Danos, PhD
  • Executive Vice President and Chief Scientific Officer
  • 2.99M
  • Mitchell Chan
  • Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  • --
  • Stephen Pakola, M.D.
  • Executive Vice President and Chief Medical Officer
  • 3.31M
  • Allan M. Fox
  • Chairman of the Board
  • 354.98K
  • Daniel Tasse
  • Lead Independent Director
  • 334.98K
  • Jennifer Zachary
  • Independent Director
  • 329.98K
  • Dr. David C. Stump,M.D.
  • Independent Director
  • 339.98K
  • Dr. Argeris N. Karabelas, PhD
  • Independent Director
  • 352.48K
  • Dr. Jean Bennett, M.D.,Pd.D
  • Independent Director
  • 324.98K
  • George V. Migausky
  • Independent Director
  • 339.98K
  • Dr. Alexandra Glucksmann, PhD
  • Independent Director
  • 327.48K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Coinbase
COIN
+7.38%
Tesla
TSLA
+3.44%
Strategy
MSTR
+3.63%
Salesforce
CRM
+2.45%
NVIDIA
NVDA
+2.01%

Unlock the Full List